Results 201 to 210 of about 2,617,552 (333)

Empirical Bayes estimation of farm prevalence adjusting for multistage sampling and uncertainty in test performance: a Brucella cross-sectional serostudy in southern Kazakhstan. [PDF]

Epidemiol Infect, 2016
Beauvais W, Orynbayev M, Guitian J.
europepmc   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

Fast 3D-HEVC Depth Map Coding Method Based on Spatio-Temporal Correlation and a Two-Stage Mode Decision Framework. [PDF]

Sensors (Basel)
Tian E, Zhang J, Zhang Q.
europepmc   +1 more source

A real‐world data‐driven approach to optimizing enoxaparin dosing in burn patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Enoxaparin dosing in burn patients is challenging due to physiological changes affecting absorption, distribution and clearance. The objectives of this study are to develop a population pharmacokinetic (PK) model for enoxaparin in burn patients, evaluate target attainment with current equation‐based (EQ) dosing and propose an optimized dosing ...
Babajide Shenkoya, Venkata Yellepeddi, Ann Marie B. Prazak, Mathangi Gopalakrishnan   +3 more
wiley   +1 more source

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

Bayesian and non-Bayesian estimation of the bivariate inverse Weibull distribution parameters using ranked set sampling with concomitant variable. [PDF]

Sci Rep
Muhammed HZ, Shaaban M.
europepmc   +1 more source

Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life‐threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK‐wide survey of local hospital protocols for the use of andexanet alfa suggested that practice ...
Louis Fisher, Richard Buka, Rosalind Byrne, Stephen Black, Helen J. Curtis, Christopher Wood, Andrew Brown, Sebastian Bacon, Richard Croker, Ben Goldacre, Brian MacKenna, Victoria Speed   +11 more
wiley   +1 more source

Bayes Factor Tests for Group Differences in Ordinal and Binary Graphical Models. [PDF]

Psychometrika
Marsman M, Waldorp LJ, Sekulovski N, Haslbeck JMB.   +3 more
europepmc   +1 more source

Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure

British Journal of Clinical Pharmacology, EarlyView.
Abstract Congenital ichthyoses (CI) are rare, inherited skin disorders characterized by hyperkeratosis, scaling and fissuring that significantly impair patients' quality of life. Treatment options are limited, with systemic retinoids reserved for severe cases owing to their adverse effect profile.
Holm Schneider, Christopher G. Bunick, Kathrin Hillmann, Thy N. Huynh, Steven Kempers, Nicolai Peschel, Ulrike Blume‐Peytavi, Joyce M. C. Teng, Alan M. Mendelsohn, John Stinson, Lara Wine Lee   +10 more
wiley   +1 more source

Comparing Bayesian estimation and structural-after-measurement approaches for structural equation models with latent interactions and complex data structures. [PDF]

Behav Res Methods
Cox K, Kelcey B.
europepmc   +1 more source